Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
Author:
Affiliation:
1. Department of Oncology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Chongqing, China
Publisher
Informa UK Limited
Subject
Pharmaceutical Science,Biomedical Engineering,General Medicine,Medicine (miscellaneous),Biotechnology
Link
https://www.tandfonline.com/doi/pdf/10.1080/21691401.2019.1687499
Reference42 articles.
1. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
3. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
4. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
5. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comprehensive evaluation of PD-1 inhibitors marketed in China based on a Quick Guideline for drug evaluation and selection in Chinese Medical Institutions (second edition);Intelligent Pharmacy;2024-08
2. Atypical artificial cells: Novel biomimetic materials for combating cancer;Interdisciplinary Materials;2024-07-17
3. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer;International Immunopharmacology;2022-07
4. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies;Frontiers in Oncology;2022-05-10
5. Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors;Expert Opinion on Biological Therapy;2021-06-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3